B. Kynast

1.1k total citations · 1 hit paper
11 papers, 970 citations indexed

About

B. Kynast is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, B. Kynast has authored 11 papers receiving a total of 970 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Molecular Biology. Recurrent topics in B. Kynast's work include Radiopharmaceutical Chemistry and Applications (3 papers), Metal complexes synthesis and properties (3 papers) and Testicular diseases and treatments (2 papers). B. Kynast is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (3 papers), Metal complexes synthesis and properties (3 papers) and Testicular diseases and treatments (2 papers). B. Kynast collaborates with scholars based in Germany and Austria. B. Kynast's co-authors include Bernhard K. Keppler, Christian G. Hartinger, Stefanie Zorbas‐Seifried, Haralabos Zorbas, Michael A. Jakupec, Hans‐Joachim Schmoll, Barbara Zoll, A. Schauer, Carsten Bokemeyer and Lutz Binder and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and European Journal of Cancer.

In The Last Decade

B. Kynast

11 papers receiving 958 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)

2006 860 citations Christian G. Hartinger, Stefanie Zorbas‐Seifried et al. Journal of Inorganic Biochemistry profile →

Peers

Countries citing papers authored by B. Kynast

Since Specialization

Citations

This map shows the geographic impact of B. Kynast's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Kynast with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Kynast more than expected).

Fields of papers citing papers by B. Kynast

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Kynast. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Kynast. The network helps show where B. Kynast may publish in the future.

Co-authorship network of co-authors of B. Kynast

This figure shows the co-authorship network connecting the top 25 collaborators of B. Kynast. A scholar is included among the top collaborators of B. Kynast based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Kynast. B. Kynast is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A) breakdown → 2006 ·Journal of Inorganic Biochemistry ·Christian G. Hartinger, Stefanie Zorbas‐Seifried, Michael A. Jakupec, B. Kynast, Haralabos Zorbas, Bernhard K. Keppler	860
2	620: Distribution and Effectivity of Ki-67 Antisense Oligonucleotides after Intravesical Application in a Bladder Cancer Model 2006 ·The Journal of Urology ·(unknown), Ingo Kausch, B. Kynast, (unknown), Christian Doehn, D. Jocham	1
3	A phase I dose-escalation trial with the new redox activated compound sodium trans-[tetrachlorobis(1 H-indazole)ruthenate(III)]/indazolhydrochloride (1:1.1) (FFC14A) in patients with solid tumors - a CESAR study 2004 ·Journal of Clinical Oncology ·M. E. Scheulen, B. Kynast, Ulrich Jaehde, (unknown), Eberhard Scheuch, Vladimir B. Arion, P. Kupsch, (unknown), Christian Dittrich, Bernhard K. Keppler	1
4	A phase I dose-escalation trial with the new redox activated compound sodium trans-[tetrachlorobis(1 H-indazole)ruthenate(III)]/indazolhydrochloride (1:1.1) (FFC14A) in patients with solid tumors - a CESAR study 2004 ·Journal of Clinical Oncology ·M. E. Scheulen, B. Kynast, Ulrich Jaehde, (unknown), Eberhard Scheuch, Vladimir B. Arion, P. Kupsch, (unknown), Christian Dittrich, Bernhard K. Keppler	6
5	Hematopoietic growth factors and treatment of testicular cancer: Biological interactions, routine use and dose-intensive chemotherapy 1996 ·Annals of Hematology ·Carsten Bokemeyer, M.A. Kuczyk, (unknown), Hermann Einsele, B. Kynast, Hans‐Joachim Schmoll	23
6	No synergistic activity of epirubicin and interferon-?2b in the treatment of hepatocellular carcinoma 1995 ·Cancer Chemotherapy and Pharmacology ·C. Bokemeyer, B. Kynast, A. Harstrick, (unknown), (unknown), Peter von Wussow, Hans‐Joachim Schmoll	1
7	No synergistic activity of epirubicin and interferon-α2b in the treatment of hepatocellular carcinoma 1995 ·Cancer Chemotherapy and Pharmacology ·(unknown), B. Kynast, A. Harstrick, (unknown), (unknown), Peter von Wussow, Hans‐Joachim Schmoll	16
8	Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients 1993 ·Journal of Cancer Research and Clinical Oncology ·B. Kynast, Lutz Binder, D Marx, Barbara Zoll, Hans‐Joachim Schmoll, Michael Oellerich, A. Schauer	32
9	Comparison of 5 vs 10 μg/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer 1993 ·Annals of Hematology ·Carsten Bokemeyer, Hans‐Joachim Schmoll, Bernd Metzner, J. Beyer, H. J. Illiger, Michael Kneba, Helmut Ostermann, B. Kynast, U. Räth, H. Poliwoda	7
10	Ototoxicity following therapy for testicular cancer 1993 ·European Journal of Cancer ·Carsten Bokemeyer, C. Berger, B. Kynast, Hans‐Joachim Schmoll, H. Poliwoda	7
11	Alterations of the c-erbB2 gene in human breast cancer 1992 ·Journal of Cancer Research and Clinical Oncology ·Barbara Zoll, B. Kynast, (unknown), (unknown), G. Fischer, A. Schauer	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact